Neuroendocrine Carcinoma Market Report 2026

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.88 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising prevalence of neuroendocrine carcinoma, increased use of imaging for early detection, early adoption of surgical tumor removal, development of initial chemotherapy protocols, growing clinical awareness of nec subtypes.

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to expanding use of targeted biologic therapies, rising investment in immunotherapy research, increasing availability of precision diagnostic tools, development of advanced radiotherapy systems, growing adoption of multidisciplinary oncology centers. Major trends in the forecast period include rising adoption of chemotherapy for aggressive tumor management, increasing use of targeted therapies in advanced nec cases, growing utilization of radiotherapy for localized tumor control, expansion of biopsy and serology-based diagnostic approaches, increasing demand for multidisciplinary treatment planning.

The growth of targeted therapies is expected to drive the expansion of the neuroendocrine carcinoma market in the coming years. Targeted therapies are designed to precisely interfere with the molecular mechanisms or genetic alterations that drive diseases such as cancer. Demand for these therapies is rising due to their ability to treat specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma provides opportunities for the development of targeted therapies that address the tumor’s unique genetic and biochemical profile, enhancing treatment precision and effectiveness. For instance, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, and Citeline, a US-based provider of drug and device information, reported that the number of gene therapies in Phase II trials increased by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2. Therefore, the rise of targeted therapies is driving growth in the neuroendocrine carcinoma market.

Key companies in the neuroendocrine carcinoma market are developing advanced solutions, such as targeted radiopharmaceutical therapy, to improve treatment accuracy and patient outcomes. Targeted radiopharmaceutical therapy uses radioactive molecules to selectively deliver radiation to cancer cells, minimizing damage to surrounding healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received FDA orphan drug designation for ABD-147 to treat neuroendocrine carcinoma. ABD-147 targets tumors expressing the DLL3 protein, which is frequently upregulated in aggressive neuroendocrine cancers, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The orphan drug designation provides advantages such as tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a promising therapy in this specialized oncology segment.

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. This acquisition strengthens Bristol-Myers Squibb’s oncology pipeline, particularly in the treatment of neuroendocrine tumors and other hard-to-treat cancers, by leveraging RayzeBio’s expertise in targeted therapies and innovative drug development. RayzeBio Inc., based in the US, specializes in treatments for gastroenteropancreatic neuroendocrine tumors.

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroendocrine carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the neuroendocrine carcinoma market by increasing the cost of imported chemotherapy drugs, targeted biologics, and diagnostic imaging equipment essential for accurate tumor evaluation. These cost increases disproportionately impact hospitals, clinics, and oncology centers in regions reliant on imported pharmaceutical and diagnostic supplies such as Europe and Asia-Pacific. Treatment segments including chemotherapy, radiotherapy, and biopsy-based diagnostics face delays, higher prices, and reduced accessibility. However, tariffs are also encouraging domestic production of oncology drugs and diagnostic tools, improving regional supply chain resilience and stimulating localized innovation.

The neuroendocrine carcinoma market research report is one of a series of new reports that provides neuroendocrine carcinoma market statistics, including neuroendocrine carcinoma industry global market size, regional shares, competitors with a neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuroendocrine carcinoma (NEC) is a rare and aggressive cancer arising from neuroendocrine cells, which possess characteristics of both nerve cells and hormone-secreting cells. These cancers can develop in multiple organs, including the lungs, pancreas, and gastrointestinal tract, and often require a combination of surgery, chemotherapy, radiotherapy, and targeted therapies for effective management.

The main types of neuroendocrine carcinoma include gastroenteropancreatic neuroendocrine tumors (GEP-NETs), carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies that originate from neuroendocrine cells within the gastrointestinal tract or pancreas. Diagnosis involves imaging techniques, biopsy, and serological testing to identify tumor type and extent. Treatments include chemotherapy, radiotherapy, surgery, targeted therapies, and other supportive care options. NEC drugs and therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, oncology clinics, specialized cancer centers, and ambulatory surgery centers.

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.